The effect of Qiliqiangxin capsules on left ventricular remodeling,heart function,N-terminal pro-brain natriuretic peptide and cardiac troponin I in patients with ischemic heart disease and heart failure
Chen Xin-hu
Abstract
Chen Xin-hu
Abstract
Objective To investigate the effect of Qiliqiangxin capsules on left ventricular remodeling,cardiac function,N-terminal pro brain natriuretic peptide(NT-proBNP) and cardiac troponin 1(cTnI) in patients with ischemic cardiomyopathy and heart failure.Methods Sixty cases of heart failure patients were randomly divided into treatment group and control group with 30 cases in each group,they were given angiotensin converting enzyme inhibitors or angiotensin Ⅱ receptor antagonists,beta blockers,diuretics,the treatment group added Qiliqiangxin capsules.6 months after treatment,clinical symptoms,left ventricular end-diastolic diameter(LVEDD),Left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF),output per minute(CO),changes of NT-proBNP,cTnI were observed and compared between the2 groups.Results Total effective rate in the treatment group was significantly higher than the control group,the difference was statistically significant(93.33%vs.80.00%,P 0.05).Compared with before treatment,the 2 groups after treatment,NT-proBNP,cTnI,LVEDD were decreased,LVEF,CO were increased significantly,the difference was statistically significant(P 0.05 or P 0.01),and 6 months after treatment,the treatment group's NT-proBNP,cTnI drop obviously,LVEDD,LVESD,LVEF,CO improved obviously compared to the same period in the control group,the difference was statistically significant(P 0.05).The treatment group hospital stay,readmission rates were lower than the control group(P 0.05).Conclusion For heart failure,on the basis of routine treatment,added Qiliqiangxin capsules could reduce the levels of cTnI,NT-proBNP,reverse left ventricular remodeling,and improve the heart function.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To investigate the effect of Qiliqiangxin capsules on left ventricular remodeling,cardiac function,N-terminal pro brain natriuretic peptide(NT-proBNP) and cardiac troponin 1(cTnI) in patients with ischemic cardiomyopathy and heart failure.Methods Sixty cases of heart failure patients were randomly divided into treatment group and control group with 30 cases in each group,they were given angiotensin converting enzyme inhibitors or angiotensin Ⅱ receptor antagonists,beta blockers,diuretics,the treatment group added Qiliqiangxin capsules.6 months after treatment,clinical symptoms,left ventricular end-diastolic diameter(LVEDD),Left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF),output per minute(CO),changes of NT-proBNP,cTnI were observed and compared between the2 groups.Results Total effective rate in the treatment group was significantly higher than the control group,the difference was statistically significant(93.33%vs.80.00%,P 0.05).Compared with before treatment,the 2 groups after treatment,NT-proBNP,cTnI,LVEDD were decreased,LVEF,CO were increased significantly,the difference was statistically significant(P 0.05 or P 0.01),and 6 months after treatment,the treatment group's NT-proBNP,cTnI drop obviously,LVEDD,LVESD,LVEF,CO improved obviously compared to the same period in the control group,the difference was statistically significant(P 0.05).The treatment group hospital stay,readmission rates were lower than the control group(P 0.05).Conclusion For heart failure,on the basis of routine treatment,added Qiliqiangxin capsules could reduce the levels of cTnI,NT-proBNP,reverse left ventricular remodeling,and improve the heart function.
Key concepts: Ejection fraction, Medicine, Internal medicine, Cardiology, Heart failure, Troponin I, Cardiac function curve, Natriuretic peptide